Effect of co-existing auto-immunity disorders on subclinical atherosclerosis To avoid the potential confounding effect of co-existing autoimmune diseases about subclinical atherosclerosis [6], all the analyses were repeated after excluding subjects with Systemic Lupus Erythematosus (SLE) or additional autoimmune diseases and, as compared with controls, a higher CCA-IMT, Bulb-IMT and prevalence of carotid plaques were confirmed in APP service providers and in APS subjects (Fig

Effect of co-existing auto-immunity disorders on subclinical atherosclerosis To avoid the potential confounding effect of co-existing autoimmune diseases about subclinical atherosclerosis [6], all the analyses were repeated after excluding subjects with Systemic Lupus Erythematosus (SLE) or additional autoimmune diseases and, as compared with controls, a higher CCA-IMT, Bulb-IMT and prevalence of carotid plaques were confirmed in APP service providers and in APS subjects (Fig. manifestations and cardiovascular risk factors, antibody isotype and Systemic Lupus Erythematosus (SLE) or additional autoimmune diseasesHow data was acquiredUltrasound machine (MyLab 25 Platinum, Esaote, Florence, Italy) having a 7.5C12?MHz linear-array transducer.Data formatMean with standard deviations analyzed with t-test for continuous data and percentages analyzed with the 2 2 test for categorical variablesData resource locationFederico II University or college, Naples, Italy Open in a separate window Value of the data We here statement data on common carotid artery intima-media thickness (CCA-IMT), intima-media thickness at the level of carotid Bulb (Bulb-IMT) and prevalence of carotid plaques in subjects with antiphospholipid syndrome (APS) and in service providers with isolated antiphospholipid antibodies positivity (APP) stratifying for the type of thrombotic manifestations, for the presence of cardiovascular risk factors, antibody ASP6432 isotype and concomitant Systemic Lupus Erythematosus (SLE) or other autoimmune diseases. Cardiovascular and immunologic variables impact on subclinical atherosclerosis and data corrected for these potential confounders are needed. These data can be useful to be combined with data from additional studies in the framework of a meta-analysis. 1.?Data Data on CCA-IMT, Bulb-IMT and on the prevalence of carotid plaques in APS subjects, in APP service providers and in matched settings stratified for the presence of thrombotic manifestations and cardiovascular risk factors, antibody isotype and Systemic Lupus Erythematosus (SLE) or other autoimmune diseases [1]. 2.?Experimental design, materials, and methods As further detailed elsewhere (http://dx.doi.org.10.1016/j.ijcard.2018.06.010) consecutive subjects having a persistent positivity for antiphospholipid antibodies (lupus anticoagulant [LA], IgG and IgM anti-cardiolipin [aCL], IgG and IgM anti-2 glycoprotein-I [a2GPI]) [2] were classified as APS in the presence of a history of an objectively documented venous and/or arterial thrombosis and/or with recurrent miscarriage or as APP when clinical history, physical exam and diagnostic methods (electrocardiogram and vascular ultrasound) excluded the presence of symptomatic and/or asymptomatic venous and/or arterial thrombotic events and of recurrent miscarriages. Data about cardiovascular risk factors were recorded according to the National Cholesterol Education System (NCEP) criteria [3]. An ultrasound assessment of carotid intima-media thickness (IMT) was performed as previously explained [4] to evaluate CCA-IMT, Bulb-IMT and the presence of carotid plaques, defined as an IMT??1.3?mm. Statistical analysis was performed with the IBM SPSS 22 system (SPSS Inc., Chicago, IL, USA). Continuous data were indicated as mean standard deviation (SD). The ideals? ?0.05. 2.1. Effect of different types of thrombotic events on subclinical atherosclerosis APS subjects with arterial thrombotic manifestations showed the highest CCA-IMT and Bulb-IMT ideals, and the highest prevalence of carotid plaques. The difference was significant both versus settings and versus APP service providers. In contrast, APS subjects with non-arterial thrombotic events ASP6432 (including venous thrombosis and recurrent miscarriage) showed a more severe atherosclerosis than settings, whereas no difference was found as compared to APP service providers (Table 1). Table ASP6432 1 Common Carotid Artery Intima-Media Thickness (CCA-IMT), intima-media thickness at the level of carotid Bulb (Bulb-IMT) and prevalence of carotid plaques in service providers of antiphospholipid antibodies positivity (APP), subjects with antiphospholipid syndrome (APS) and settings, stratified for the type of thrombotic manifestation. vs Controlsvs APPvs Controlsvs APPControls0.95 0.18Comparator0,009Arterial APS1.43 0.89 ?0.001 ?0.001Non-arterial APS1.18 0.56 ?0.0010.807APP1.10 0.450,009ComparatorCarotid Plaques (%)P vs ControlsP vs APPControls33 (10.2%)Comparator ?0.001Arterial APS24 (49.0%) ?0.0010.077Non-arterial APS61 (35.5%) ?0.0010.795APP35 (33.7%) ?0.001Comparator Open in a separate window Notice: Arterial APS includes cardiovascular and cerebrovascular events; Non-arterial APS includes venous thrombosis and recurrent miscarriage. 2.2. Effect of cardiovascular risk factors on subclinical atherosclerosis To also evaluate whether traditional cardiovascular risk factors might impact on the difference in subclinical atherosclerosis found among APS subjects, APP carriers and controls, we repeated analyses only selecting subjects without any cardiovascular risk element, and we found a CMKBR7 significantly higher CCA-IMT and Bulb-IMT having a marginally significantly higher prevalence of carotid plaques both in APP service providers and in APS subjects, as compared with settings (Table 2). Table 2 Common Carotid Artery Intima-Media Thickness (CCA-IMT), intima-media thickness at the level of carotid Bulb (Bulb-IMT) and prevalence of carotid plaques in service providers of antiphospholipid antibodies positivity (APP), subjects with antiphospholipid syndrome (APS) and settings. Sub-analysis in subjects without cardiovascular risk.